Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc-by (c) Blecua, Pedro et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/177753

The DNA methylation landscape of hematological malignancies: an update

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

The rapid advances in high-throughput sequencing technologies have made it more evident that epigenetic modifications orchestrate a plethora of complex biological processes. During the last decade, we have gained significant knowledge about a wide range of epigenetic changes that crucially contribute to some of the most aggressive forms of leukemia, lymphoma and myelodysplastic syndromes. DNA methylation is a key epigenetic player in the abnormal initiation, development and progression of these malignancies, often acting in synergy with other epigenetic alterations. It also contributes to the acquisition of drug resistance. In this review, we summarize the role of DNA methylation in hematological malignancies described in the current literature. We discuss in detail the dual role of DNA methylation in normal and aberrant hematopoiesis, as well as the involvement of this type of epigenetic change in other aspects of the disease. Finally, we present a comprehensive overview of the main clinical implications, including a discussion of the therapeutic strategies that regulate or reverse aberrant DNA methylation patterns in hematological malignancies, including their combination with (chemo-) immunotherapy.

Citació

Citació

BLECUA, Pedro, MARTINEZ-VERBO, Laura, ESTELLER, Manel. The DNA methylation landscape of hematological malignancies: an update. _Molecular Oncology_. 2020. Vol. 14, núm. 8, pàgs. 1616-1639. [consulta: 23 de gener de 2026]. ISSN: 1574-7891. [Disponible a: https://hdl.handle.net/2445/177753]

Exportar metadades

JSON - METS

Compartir registre